EUCTR2015-000825-35-DK进行中（未招募）1 期
The effect of the glucagon-like peptide-1 analogue, liraglutide (Victoza®), on jejunostomy output and intestinal absorption in short bowel syndrome patients, a double-blind cross-over study - Liraglutide (Victoza®) and Short Bowel Syndrome
Rigshospitalet Blegdamsvej0 个研究点目标入组 16 人开始时间: 2015年6月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.must give written informed consent before participation;
- •2.must be able to communicate with the investigator;
- •3.patients with SBS-IF or intestinal insufficiency with end-jejunostomy;
- •4.primary disease leading to SBS should be Mb. Crohn, volvulus, injury, mesenteric vascular disease or from benign origination;
- •5.age groups 18-90 years;
- •6.stable body weight (<5% weight deviance in past three month prior to screening);
- •7.minimum 1 liter of parental support (fluid and/or nutrition) per week or an ostomy output exceeding 1500 gram/day;
- •8.usual medicine must have been stable for at least four weeks and kept constant during whole study period;
- •9.must have an eGFR (by the MDRD formula7) >30 mL/min/1.73 m2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1.females who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods*;
- •2.systolic blood pressure > 180 mmHg;
- •3.type-1 diabetes mellitus;
- •4.chronic pancreatitis / previous acute pancreatitis;
- •5.known or suspected hypersensitivity to trial product(s) or related product;
- •6.treatment with oral glucocorticoids, calcineurin inhibitors, or DPP4 inhibitors which in the investigator’s opinion could interfere with glucose or lipid metabolism 90 days prior to screening;
- •7.cancer (except basal cell skin cancer or squamous cell skin cancer) or any other clinically significant disorder, except for conditions associated with type 2 diabetes history, which in the investigators opinion could interfere with the results of the trial;
- •8.active inflammatory bowel disease or fistula;
- •9.cardiac disease defined as: Decompensated heart failure (NYHA class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months;
- •10.known with radiation enteritis or celiac disease; known or suspected abuse of alcohol or medicine;
- •11.impaired liver function (transaminases > two times upper reference levels);
- •12.clinically meaningful renal disease; subjects with personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2;
- •13.the receipt of any investigational product 90 days prior to this trial;
- •14.administration of glutamine or other growth factors for the past three months;
- •15.upon Investigator’s judgment
- •* Please view the Danish Health and Medicine Authority guideline on which type of contraception is considered safe in clinical trials on www.sundhedsstyrelsen.dk. Intrauterine devices, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices, injections with prolonged release and vaginal rings) are considered as adequate contraceptives. Sterilized or infertile subjects are exempt from the requirement to use contraception. In order to be considered sterilized or infertile, subjects must generally have undergone surgical sterilization (vasectomy/bilateral tubectomy, hysterectomy and bilateral ovariectomy) or be postmenopausal defined as 12 months or more with no menses prior to enrolment
研究者
相似试验
已完成
1 期
The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.ACTRN12608000428369Royal Adelaide Hospital24
进行中（未招募）
1 期
GLP-1 and persons without stroke.EUCTR2016-001221-14-DKHerlev Gentofte Hospital
进行中（未招募）
1 期
GLP-1 and strokeMedDRA version: 19.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersStrokeEUCTR2016-001219-18-DKHerlev Gentofte Hospital30
已完成
2 期
Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?Blood GlucoseType-2 DiabetesMetabolic and Endocrine - DiabetesACTRN12610000185066Adam Deane10
已完成
2 期
Exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in the critically ill.Blood GlucoseMetabolic and Endocrine - Other metabolic disordersACTRN12609000093280Adam Deane8